mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways

Cancer Research

Volumn 71, Issue 9, 2011, Pages 3246-3256

  Gulhati, Pat ^a,b,c   Bowen, Kanika A ^d   Liu, Jianyu ^a,b   Stevens, Payton D ^a,b   Rychahou, Piotr G ^a,b   Chen, Min ^a,b   Lee, Eun Y ^a   Weiss, Heidi L ^a,b   O'Connor, Kathleen L ^a,b   Gao, Tianyan ^a,b   Evers, B Mark ^a,b  

^a Department of Surgery ^*  (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; OXALIPLATIN; PROTEIN MTORC1; PROTEIN MTORC2; PROTEIN RAPTOR; PROTEIN RICTOR; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ARTICLE; CANCER INVASION; CELL CONTACT; CELL MOTILITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACTINS; CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; CYTOSKELETON; EPITHELIAL-MESENCHYMAL TRANSITION; HCT116 CELLS; HUMANS; NEOPLASM METASTASIS; PROTEINS; RAC1 GTP-BINDING PROTEIN; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 79955486858     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4058     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin 2011;61:69-90.
2. Griffin MR, Bergstralh EJ, Coffey RJ, Beart RW Jr, Melton LJ 3rd. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 1987;60:2318-24. (Pubitemid 17153502)
3. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
4. Wu Y, Zhou BP. New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai) 2008;40:643-50. (Pubitemid 352009085)
5. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998;279:509-14.
6. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, et al. The phosphatidylinositol 30-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426-9. (Pubitemid 32995029)
7. Roy HK , Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002;23:201-5. (Pubitemid 34213570)
8. Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 2006;243:833-42; discussion 843-4.
9. Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY, et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A 2008;105:20315-20.
10. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. (Pubitemid 47001784)
11. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68.
12. Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, et al. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res 2009;15:7207-16.
13. Bowen KA, Doan HQ, Zhou BP, Wang Q, Zhou Y, Rychahou PG, et al. PTEN loss induces epithelial-mesenchymal transition in human colon cancer cells. Anticancer Res 2009;29:4439-49.
14. Larson Y, Liu J, Stevens PD, Li X, Li J, Evers BM, et al. Tuberous sclerosis complex 2 (TSC2) regulates cell migration and polarity through activation of CDC42 and RAC1. J Biol Chem 2010;285:24987-98.
15. O'Connor KL, Nguyen BK, Mercurio AM. RhoA function in lamellae formation and migration is regulated by the alpha6beta4 integrin and cAMP metabolism. J Cell Biol 2000;148:253-8. (Pubitemid 30078237)
16. Kende AI, Carr NJ, Sobin LH. Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract. Histopathology 2003;42:137-40. (Pubitemid 36237845)
17. Liu L, Li F, Cardelli JA, Martin KA, Blenis J, Huang S. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4EBP1 pathways. Oncogene 2006;25:7029-40. (Pubitemid 44722071)
18. Liu L, Chen L, Chung J, Huang S. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 2008;27:4998-5010.
19. Zhang F, Zhang X, Li M, Chen P, Zhang B, Guo H, et al. mTOR complex component Rictor interacts with PKC{zeta} and regulates cancer cell metastasis. Cancer Res 2010:70:9360-70.
20. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument- Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-302. (Pubitemid 38991819)
21. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122-8. (Pubitemid 39468014)
22. Moss SC, Lightell DJ Jr, Marx SO, Marks AR, Woods TC. Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem 2010;285:11991-7.
23. Liu L, Luo Y, Chen L, Shen T, Xu B, Chen W, et al. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J Biol Chem 2010;285: 38362-73.
24. Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007;178:437-51. (Pubitemid 47196152)